SCHEMBL3012829

SCHEMBL3012829

Cc1ccc(F)cc1S(=O)(=O)C1CCN(c2nc(-c3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.52
NPSR1 Q6W5P4 1/20 0.41
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 5/20 0.39
ALDH1A1 P00352 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CTSS P25774 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
FAAH O00519 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015205 0.90 AR (0.54) ARNPSR1MAPK1SMN1; SMN2ALDH1A1
SCHEMBL3019537 0.89 AR (0.53) ARNPSR1MAPK1SMN1; SMN2ALDH1A1
SCHEMBL3008199 0.88 MAPK1 (0.51) ARNPSR1MAPK1SMN1; SMN2ALDH1A1
SCHEMBL3014988 0.87 MAPK1 (0.47) ARNPSR1MAPK1SMN1; SMN2ALDH1A1
SCHEMBL3018656 0.86 AR (0.54) ARNPSR1MAPK1SMN1; SMN2MEN1
SCHEMBL3013685 0.86 AR (0.54) ARNPSR1MAPK1SMN1; SMN2ALDH1A1
SCHEMBL3002708 0.86 AR (0.56) ARNPSR1MAPK1SMN1; SMN2ALDH1A1
SCHEMBL3005795 0.86 AR (0.60) ARNPSR1MAPK1SMN1; SMN2CTSS
SCHEMBL3005274 0.86 MAPK1 (0.46) ARMAPK1SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3016015 0.85 SMN1; SMN2 (0.46) ARMAPK1SMN1; SMN2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885NPSR1 764/4885MAPK1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.